News

Pursuant to the license agreement, TAGI Pharma is expected to market and sell four Elite generic products in the US, Puerto Rico and Canada. Elite will receive a

The launch of the trial is based on the positive GFT505-209-4 and GFT505-109-6 studies, demonstrating the insulin-sensitizing effects of GFT505 in non-diabetic subjects. International scientific coordinator of the

Cyprotex and TB Alliance aim to discover TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB

Bivium plans to introduce Cellerate RX to the Panamian health-care community at the Congress of the Panamanian Association of General Surgery conference in Panama City. The addition of

Lorcaserin is the subject of an exclusive licensing agreement concluded between Eisai’s US subsidiary Eisai Inc and Arena Pharmaceuticals GmbH, the wholly-owned Swiss subsidiary of Arena Pharmaceuticals Inc,

NewCardio’s QTinno is a software suite that provides automated, comprehensive cardiac safety analysis as defined in the ICH E14 Guidance for Clinical Evaluation of QT/QTc interval prolongation and

PrimeSuite 2011 is a pre-market CCHIT Certified 2011 Ambulatory EHR, additionally certified for Child Health and Cardiovascular Medicine, with optional Advanced Reporting. VHA Purchased Services and Strategic Outsourcing

The trial was a randomised, double-blind, placebo-controlled study in 150 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of

Alkermes said that the FDA will consider the Advisory Committee’s recommendation in its review of the supplemental new drug application (sNDA) that the company has submitted for Vivitrol.